Background Higher medication adherence reduces the risk of new cardiovascular events.
However, there are individual and health system barriers that lead to lower adherence. The …

Introduction Combination therapies continue to improve therapeutic outcomes as currently
achieved by polypharmacy. Since the introduction of the polypill, there has been a …

Randomized controlled trials (RCTs) examining the outcomes of “polypill” therapy in
cardiovascular disease prevention have yielded mixed results. We performed an electronic …

Fixed-dose combination (FDC) therapy, also known as polypill therapy, targets risk factors
for atherosclerotic cardiovascular disease (ASCVD) and has been proposed as a strategy to …

Aims We aimed to perform a systematic review and meta-analysis of randomized controlled
trials (RCTs) to determine the impact of a polypill-based strategy (PBS) on therapeutic …

A significant global health concern, cardiovascular disease (CVD) is characterized by a
rising prevalence and accompanying mortality rates. It is crucial to implement primary and …

Cardiovascular disease (CVD) is a significant cause of death worldwide. To address the
global burden of CVD and its risk factors, the polypill, an all-in-one therapy that combines …

Transcatheter aortic valve replacement (TAVR) has emerged as an effective therapy for
patients with severe aortic stenosis, irrespective of surgical risks. 1 Stroke due to cerebral …

Background Predicted heart age (PHA) can simplify communicating the absolute
cardiovascular disease (CVD) risk. Few studies have characterized PHA across multiple …

Cardiovascular disease continues to be the leading cause of mortality globally. Modifiable
risk factors, such as hypertension and dyslipidemia can be managed through lifestyle and …